• Vittoria Biotherapeutics

  Led · Equity · Nov 2024

  Vittoria Biotherapeutics is a clinical-stage immunotherapy company developing novel cell therapies for hard-to-treat diseases. Its lead program, VIPER-101, is a gene-edited, autologous dual-population T cell therapy designed to target CD5 for patients with T-cell lymphoma. VIPER-101 and other assets leverage the company’s proprietary Senza5 platform, which enhances T cell effector function by abrogating CD5-mediated immunosuppression and employs a rapid five-day manufacturing process. Senza5 has demonstrated outstanding preclinical anti-tumor efficacy across a range of liquid and solid tumor models, and the broader pipeline includes programs targeting solid tumors and autoimmune diseases. The company recently completed a $25 million private financing to support clinical proof-of-concept for VIPER-101. The VIPER-101 Phase 1 trial is actively recruiting patients (ClinicalTrials.gov NCT06420089). The technology is exclusively licensed from the University of Pennsylvania, which also holds equity and has existing financial relationships with Vittoria.

No current team members are available.